April blir en spennende måned for de som har NANO i porteføljen sin:
Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and oncology,
announces that a late-breaking abstract on its Phase 1/2 clinical study with
Betalutin has been accepted for presentation at the American Association For
Cancer Research (AACR) annual meeting (16-20 April 2016, New Orleans, LA, USA).
The poster will provide an update of safety, clinical results and duration of
response (DOR) from its ongoing Phase 1/2 study in subjects with relapsed non
-Hodgkin lymphoma (NHL).